We are live on !
Find out more
Dmitry Balyasny Balyasny Asset Management
AUM
$80.2B
Turnover
42.78%
1-Year Est. Return
51.53%
Dmitry Balyasny is the founder of Balyasny Asset Management, a major multi-strategy and multi-manager hedge fund platform. The firm allocates capital across fundamental equities, macro, quant, and other teams under a central risk framework. Balyasny’s platform is often cited alongside other leading pod-shop multi-strategy firms.
This Fund
S&P 500
This Quarter Est. Return
+19.41%
1 Year Est. Return
+51.53%
3 Year Est. Return
+149.76%
5 Year Est. Return
+199.38%
10 Year Est. Return
+875.18%
AUM
$80.2B
AUM Growth
+$3.12B
(+4%)
Cap. Flow
-$3.01B
Cap. Flow % of AUM
Cap. Flow %
-3.76%
Top 10 Holdings %
Top 10 Hldgs %
13.57%
Holding
3,665
New
834
Increased
989
Reduced
995
Closed
734
Avg Time Held
Equity + Options
1.1
years
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
0.8
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpaceX
SPCX
|
+$577M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$538M |
| 3 |
iShares Core S&P 500 ETF
IVV
|
+$517M |
| 4 |
Texas Instruments
TXN
|
+$413M |
| 5 |
Roku
ROKU
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Hologic
HOLX
|
+$357M |
| 2 |
Meta Platforms (Facebook)
META
|
+$326M |
| 3 |
Johnson Controls International
JCI
|
+$303M |
| 4 |
Applied Materials
AMAT
|
+$285M |
| 5 |
Coterra Energy
CTRA
|
+$285M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 36.95% |
| 2 | Technology | 12.69% |
| 3 | Industrials | 10% |
| 4 | Consumer Discretionary | 7.97% |
| 5 | Healthcare | 7.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2851
Franklin Street Properties
FSP
$44.9M
| $6.81K | ﹤0.01% |
+13,229
| New | +$7.83K |
2026 Q2
0 quarters
|
|
2852
PLAYSTUDIOS Inc
MYPS
$56.2M
| $5.99K | ﹤0.01% |
+1,201
| New | +$5.78K |
2026 Q2
0 quarters
|
|
2853
Hain Celestial
HAIN
$13.6M
| $5.97K | ﹤0.01% |
+10,651
| New | +$7.9K |
2026 Q2
0 quarters
|
|
2854
Opendoor Technologies Inc Series A Warrants
OPENL
$1.06M
| $5.92K | ﹤0.01% |
20,938
-3,030
| -13% | -$930 |
2025 Q4
2 quarters
|
|
|
2855
Opendoor Technologies Inc Series Z Warrants
OPENZ
$1.17M
| $5.92K | ﹤0.01% |
24,661
| – | – |
2025 Q4
2 quarters
|
|
2856
Charter Communications
CHTR
$13.5B
| $3.56K | ﹤0.01% |
25
-1,260
| -98% | -$210K |
2025 Q4
2 quarters
|
|
2857
Accuray
ARAY
$331K
| $3.35K | ﹤0.01% |
+13,007
| New | +$4.84K |
2026 Q2
0 quarters
|
|
2858
Rani Therapeutics
RANI
$63.1M
| $1.68K | ﹤0.01% |
2,206
-3,693
| -63% | -$3.27K |
2025 Q4
2 quarters
|
|
2859
ClearPoint Neuro
CLPT
$276M
| $892 | ﹤0.01% |
+50
| New | +$625 |
2026 Q2
0 quarters
|
|
2860
American Assets Trust
AAT
$1.32B
| – | – |
-13,181
| Closed | -$243K | – |
|
2861
Ameris Bancorp
ABCB
$5.49B
| – | – |
-4,587
| Closed | -$358K | – |
|
2862
Abeona Therapeutics
ABEO
$238M
| – | – |
-589,847
| Closed | -$2.64M | – |
|
2863
ABM Industries
ABM
$3.1B
| – | – |
-25,886
| Closed | -$997K | – |
|
2864
Arbutus Biopharma
ABUS
$723M
| – | – |
-125,521
| Closed | -$565K | – |
|
2865
ACI Worldwide
ACIW
$6.01B
| – | – |
-25,301
| Closed | -$1.04M | – |
|
2866
DELISTED
Arcellx
ACLX
| – | – |
-479,763
| Closed | -$55.1M | – |
|
2867
ACM Research
ACMR
$3.11B
| – | – |
-47,076
| Closed | -$1.85M | – |
|
2868
Aecom
ACM
$8.59B
| – | – |
-267,610
| Closed | -$22.7M | – |
|
2869
ADC Therapeutics
ADCT
$202M
| – | – |
-77,947
| Closed | -$292K | – |
|
2870
Aegon
AEG
$12.1B
| – | – |
-81,736
| Closed | -$593K | – |
|
2871
Aehr Test Systems
AEHR
$1.75B
| – | – |
-16,262
| Closed | -$603K | – |
|
2872
American Eagle Outfitters
AEO
$3.34B
| – | – |
-504,519
| Closed | -$8.43M | – |
|
2873
Affirm
AFRM
$23.1B
| – | – |
-1,149,661
| Closed | -$75.1M | – |
|
2874
Agios Pharmaceuticals
AGIO
$1.76B
| – | – |
-18,009
| Closed | -$609K | – |
|
2875
Argan
AGX
$3.89B
| – | – |
-809
| Closed | -$441K | – |
|
Similar funds
Dmitry Balyasny's Q2 2026 Portfolio in Review
As of Q2 2026, Dmitry Balyasny held 3,665 positions worth $80.2B, up 4% from $77.1B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Dmitry Balyasny withdrew a net $3.01B in Q2 2026, closing 734 positions and reducing 995 holdings. Its most notable exit was Hologic, an estimated $357M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 37% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.
Against the trend, Dmitry Balyasny opened a new position in SpaceX worth $581M.
- Dmitry Balyasny's largest Q2 2026 buy was SpaceX: 3,397,642 shares worth $581M.
- Dmitry Balyasny added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $538M increase.
- Dmitry Balyasny's biggest Q2 2026 reduction was Meta Platforms (Facebook), cutting an estimated $326M.
- Dmitry Balyasny fully exited Hologic in Q2 2026, selling an estimated $357M.
- Dmitry Balyasny's ten largest holdings make up 14% of its $80.2B portfolio in Q2 2026.
- Dmitry Balyasny opened 834 new positions and closed 734 in Q2 2026.
- Dmitry Balyasny's portfolio value rose 4% quarter-over-quarter to $80.2B.
Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.